Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Forty Seven's 3-Year RORE % for the quarter that ended in Dec. 2019 was 0.00%.
The industry rank for Forty Seven's 3-Year RORE % or its related term are showing as below:
FTSV's 3-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -7.56 * Ranked among companies with meaningful 3-Year RORE % only.
Forty Seven 3-Year RORE % Historical Data
The historical data trend for Forty Seven's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Forty Seven's 3-Year RORE %
For the Biotechnology subindustry, Forty Seven's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forty Seven's 3-Year RORE % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Forty Seven's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Forty Seven's 3-Year RORE % falls into.
Forty Seven 3-Year RORE % Calculation
Forty Seven's 3-Year RORE % for the quarter that ended in Dec. 2019 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2019 and 3-year before.
Forty Seven (NAS:FTSV) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Forty Seven 3-Year RORE % Related Terms
Thank you for viewing the detailed overview of Forty Seven's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FTSV has been successfully added to your 